Fetuin A as a Predictor of Deterioration of Renal Function in Hypertonic Patients
Recruiting · NCT05963126 · Observational (researchers observe without assigning treatment) · Lead sponsor: University Hospital Ostrava
View the official record on ClinicalTrials.gov →Interventions studied
No intervention.
What this trial is about
Commonly used parameters (creatinine, estimated glomerular filtration rate, and urine albumin/creatinine ratio) for prediction of decline of renal function are sensitive for advanced kidney impairment. Modified human urine Fetuin A (urine Fetuin A) with specific modification in urine (Fetuin A) can earlier predict the progression of kidney disease in patients with diabetes. Studies evaluating urine Fetuin A in hypertonic patients are still lacking.
Who can take part
Age range
18 Years to 100 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Arterial hypertension treated by at least one antihypertensive agent
Exclusion criteria
- Diabetes mellitus of any type, defined as fasting glucose \>7,0 mmol/l or any glycemia \>11,0 mmol/l, or HbA1c\>48 mmol/mol
- Decompensated arterial hypertension defined as office blood pressure \>180/110 mmHg or on Ambulatory Blood Pressure Monitoring (ABPM)
- Patient with renal replacement therapy
- Present rheumatoid disease (rheumatoid arthritis, systemic lupus, sclerodermia, dermatomyositis, Inflammatory Bowel Disease, etc.), positivity of antinuclear antibody (ANA) / extractable nuclear antigen (ENA) screening
- Acute infection defined as C-Reactive Protein (CRP) \>50 mg/l
- Severe impairment of liver function defined as cirrhosis, Alanine Transaminase or ASpartate Transferase (ALT or AST) \>10 µkat/l
- Terminal incurable illness
Where it is running
1 location listed.
- University Hospital Ostrava, - Department of Internal Medicine and Cardiology - Ostrava, Czech Republic, Czechia